ERAXIS (Pfizer Australia Pty Ltd)
Product name
ERAXIS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
167 (255 working days)
Active ingredients
anidulafungin
Registration type
EOI
Indication
ERAXIS (powder for injection) is now also indicated for the treatment of invasive candidiasis, including candidaemia in adult and in paediatric patients one month and older (see Section 5.1).